RIBONUCLEASE ACTIVITY AS POSSIBLE DIAGNOSTIC AND PROGNOSIS MARKER OF PROSTATE CANCER
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-23-3-2021-g.9665Keywords:
Gleason scale, prostate cancer, prostate-specific antigen, ribonuclease activityAbstract
Aim: to investigate the relationship between the level of ribonuclease (RNase) activity in the prostate tumor, in the biological fluids and the clinical and pathological features of the neoplastic process of patients with prostate cancer (PCa). Evaluate the possibility of their use as diagnostic and prognostic criteria for personalized assessment of the development and course of PCa and for the development of new schemes of personalized treatment (prediction of the sensitivity of malignant tumor to antitumor agents). Object and methods: the study used samples of tumor tissue, peripheral blood and urine of 120 patients with different stages of PCa (T1-T4) (mean age was 65.0 ± 7.88 years) and 30 patients with prostatic intraepithelial invasion (PIN) (mean age was 60,2 ± 3.6 years). The RNase activity was determined by zymogram using electrophoresis in 15% polyacrylamide gel. Results: the gradual decrease of the RNases activity in prostate tissue with the progression of PCa was found (from 460.8 ± 20.3AU to 103.5 ± 22.9 AU). At the same time, there is an increase in the level of prostate-specific antigen (PSA) in the blood plasma of patients and the degree of the spread of the process, according to the Gleason scale. It was found that erythrocytes cytosol and urine show the highest enzymatic activity in donors. Conclusions: in tumor tissue a gradual decrease of the RNase activity during the progressing of tumor growth was found. In erythrocytes cytosol of patients with PCa a decrease of the RNase activity was observed in comparison to donors. An increase of the RNase activity in the blood plasma of PCa patients with the Gleason scale (≥7) was found. The obtained data show that the RNase activity may be additional biomarker for the diagnosis and choosing tactics for personalized treatment of PCa patients.
References
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46 (4): 765–81.
Rosario S. Polyamine Biosynthetic Metabolic Dysregulation: Targeting and the Adaptive Response. 2020.
Shlyakhovenko VO. Ribonucleases. Possible new approach in cancer therapy. Exp Oncol 2016; 38 (1): 2–8.
Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42 (7): 1805–12.
Shook SJ, Beuten J, Torkko KC, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin cancer Res 2007; 13 (19): 5959–64.
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. John Wiley & Sons, 2016.
Popescu LM. Adaptation Biology and Medicine. Alpha Science International Limited, 2013.
Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992; 23 (3): 273–9.
Yasuda T, Nadano D, Tenjo E, et al. The zymogram method for detection of ribonucleases after isoelectric focusing: analysis of multiple forms of human, bovine, and microbial enzymes. Anal Biochem 1992; 206 (1): 172–7.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227 (5259): 680–5.
Yen Y, Green PJ. Identification and properties of the major ribonucleases of Arabidopsis thaliana. Plant Physiol 1991; 97 (4): 1487–93.
Cussenot O, Valeri A, Berthon P, et al. Hereditary prostate cancer and other genetic predispositions to prostate cancer. Urol Int 1998; 60 (2): 30–4.
Xiang Y, Wang Z, Murakami J, et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2′, 5′-oligoadenylates. Cancer Res 2003; 63 (20): 6795–801.
Sakakibara R, Hashida K, Kitahara T, et al. Characterization of a unique nonsecretory ribonuclease from urine of pregnant women. J Biochem 1992; 111 (3): 325–30.
Thomas JM, Crisp M, Hodes ME. Sialic acid residues contribute to the heterogeneity of human serum ribonuclease: demonstration by isoelectric focusing and neuraminidase treatment of serum. Clin Chim acta 1984; 142 (1): 73–81.
Mizuta K, Awazu S, Yasuda T, et al. Purification and characterization of three ribonucleases from human kidney: comparison with urine ribonucleases. Arch Biochem Biophys 1990; 281 (1): 144–51.
Silva CS, Moutinho C, da Vinha A, et al. Trace Minerals in Human Health: Iron, Zinc, Copper, Manganese and Fluorine. Int J Sci Res Methodol 2019; 13 (3): 57–80.
Bhagavan NV, Ha C-E. Essentials of medical biochemistry: with clinical cases. Academic Press, 2011.
Crichton RR. Biological inorganic chemistry: a new introduction to molecular structure and function. Elsevier, 2012.
Sandstead HH. Zinc deficiency: a public health problem? Am J Dis Child 1991; 145 (8): 853–9.
Czajkowska B, Naskalski JW, Sznajd J. Ribonuclease from cytosolic fraction of human erythrocytes. Clin Chim Acta 1986; 154 (1): 19–27.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424.
Ying M, Zhao R, Jiang D, et al. Lifestyle interventions to alleviate side effects on prostate cancer patients receiving androgen deprivation therapy: a meta-analysis. Jpn J Clin Oncol 2018; 48 (9): 827–34.
Arancio W, Belmonte B, Castiglia M, et al. Tissue Versus Liquid Biopsy: Opposite or Complementary? In: Liquid Biopsy in Cancer Patients. Springer, 2017: 41–9.
Ghosh RK, Pandey T, Dey P. Liquid biopsy: a new avenue in pathology. Cytopathology 2019; 30 (2): 138–43.
